- Home
- HNI vs KNSA Comparison
HNI vs KNSA Comparison
Compare HNI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNI
- KNSA
- Stock Information
- Founded
- HNI 1944
- KNSA 2015
- Country
- HNI United States
- KNSA United Kingdom
- Employees
- HNI N/A
- KNSA N/A
- Industry
- HNI Office Equipment/Supplies/Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- HNI Consumer Discretionary
- KNSA Health Care
- Exchange
- HNI Nasdaq
- KNSA Nasdaq
- Market Cap
- HNI 2.0B
- KNSA 1.9B
- IPO Year
- HNI N/A
- KNSA 2018
- Fundamental
- Price
- HNI $46.51
- KNSA $27.36
- Analyst Decision
- HNI Strong Buy
- KNSA Strong Buy
- Analyst Count
- HNI 2
- KNSA 5
- Target Price
- HNI $66.50
- KNSA $38.80
- AVG Volume (30 Days)
- HNI 337.4K
- KNSA 474.9K
- Earning Date
- HNI 05-07-2025
- KNSA 07-22-2025
- Dividend Yield
- HNI 2.92%
- KNSA N/A
- EPS Growth
- HNI 100.29
- KNSA N/A
- EPS
- HNI 2.80
- KNSA N/A
- Revenue
- HNI $2,538,200,000.00
- KNSA $481,166,000.00
- Revenue This Year
- HNI $5.21
- KNSA $37.21
- Revenue Next Year
- HNI $3.24
- KNSA $5.32
- P/E Ratio
- HNI $16.61
- KNSA N/A
- Revenue Growth
- HNI N/A
- KNSA 59.45
- 52 Week Low
- HNI $39.76
- KNSA $17.38
- 52 Week High
- HNI $58.42
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- HNI 54.29
- KNSA 62.48
- Support Level
- HNI $45.34
- KNSA $26.28
- Resistance Level
- HNI $47.32
- KNSA $27.90
- Average True Range (ATR)
- HNI 0.87
- KNSA 0.99
- MACD
- HNI -0.15
- KNSA -0.07
- Stochastic Oscillator
- HNI 21.57
- KNSA 82.30
About HNI HNI Corporation
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.